TY-9591 Clinical Trials
2 recruitingDrug
Phase 21Phase 31
Showing 1–2 of 2 trials
Recruiting
Phase 2
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NSCLCBrain MetastasesEGFR Activating Mutation
TYK Medicines, Inc420 enrolled1 locationNCT05948813
Recruiting
Phase 3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NSCLCEGFR Activating Mutation
TYK Medicines, Inc680 enrolled2 locationsNCT05382728